Cargando…
Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial
BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 rec...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120814/ https://www.ncbi.nlm.nih.gov/pubmed/37089913 http://dx.doi.org/10.2147/NDT.S408314 |
_version_ | 1785029248701956096 |
---|---|
author | Wang, Zhongbao Zheng, Yunshao Fan, Yunli Fan, Yunming Su, Xianbiao Wang, Bingrui Li, Jing Chen, Diancai Sun, Fengxia Li, Shen Ma, Jiashu Li, Xianwei Bai, Ludong Li, Ranran |
author_facet | Wang, Zhongbao Zheng, Yunshao Fan, Yunli Fan, Yunming Su, Xianbiao Wang, Bingrui Li, Jing Chen, Diancai Sun, Fengxia Li, Shen Ma, Jiashu Li, Xianwei Bai, Ludong Li, Ranran |
author_sort | Wang, Zhongbao |
collection | PubMed |
description | BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 receptors (DRD2) and dopamine transporter (DAT) and significantly reversed the expression of DRD2 and DAT. Therefore, we hypothesized that PGD might effectively improve hyperprolactinemia and alleviate sexual dysfunction in patients. METHODS: We performed an 8-week randomized controlled study on 62 subjects with schizophrenia who were randomized into two groups. The experimental group was treated with the PGD intervention, and the control group did not receive treatment. The primary outcome indicators were the levels of sex hormones and the total Arizona Sexual Experience Scale (ASEX) score. RESULTS: There was a significant difference in PRL levels between the two groups at weeks 4 and 8. From the beginning to the end of the experiment, there was a significant increase in PRL levels in the control group, while there was no significant change in the experimental group. The ASEX scale assessed sexual function in both groups, and patients in the experimental group showed an improvement in sexual function at week 8. During the experiment, the two groups found no differences between Positive and Negative Syndrome Scale (PANSS) scores and Treatment Emergent Symptom Scale (TESS) scores. CONCLUSION: PGD significantly improved the patient’s sexual function but was less effective in reducing prolactin levels and may prevent further increases in prolactin levels. |
format | Online Article Text |
id | pubmed-10120814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-101208142023-04-22 Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial Wang, Zhongbao Zheng, Yunshao Fan, Yunli Fan, Yunming Su, Xianbiao Wang, Bingrui Li, Jing Chen, Diancai Sun, Fengxia Li, Shen Ma, Jiashu Li, Xianwei Bai, Ludong Li, Ranran Neuropsychiatr Dis Treat Clinical Trial Report BACKGROUND: Most antipsychotic drugs are dopamine receptor antagonists that usually lead to abnormal increases in prolactin concentrations and the development of hyperprolactinemia (HPRL), which in turn causes sexual dysfunction in patients. Peony-Glycyrrhiza Decoction (PGD) enhanced dopamine D2 receptors (DRD2) and dopamine transporter (DAT) and significantly reversed the expression of DRD2 and DAT. Therefore, we hypothesized that PGD might effectively improve hyperprolactinemia and alleviate sexual dysfunction in patients. METHODS: We performed an 8-week randomized controlled study on 62 subjects with schizophrenia who were randomized into two groups. The experimental group was treated with the PGD intervention, and the control group did not receive treatment. The primary outcome indicators were the levels of sex hormones and the total Arizona Sexual Experience Scale (ASEX) score. RESULTS: There was a significant difference in PRL levels between the two groups at weeks 4 and 8. From the beginning to the end of the experiment, there was a significant increase in PRL levels in the control group, while there was no significant change in the experimental group. The ASEX scale assessed sexual function in both groups, and patients in the experimental group showed an improvement in sexual function at week 8. During the experiment, the two groups found no differences between Positive and Negative Syndrome Scale (PANSS) scores and Treatment Emergent Symptom Scale (TESS) scores. CONCLUSION: PGD significantly improved the patient’s sexual function but was less effective in reducing prolactin levels and may prevent further increases in prolactin levels. Dove 2023-04-17 /pmc/articles/PMC10120814/ /pubmed/37089913 http://dx.doi.org/10.2147/NDT.S408314 Text en © 2023 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Wang, Zhongbao Zheng, Yunshao Fan, Yunli Fan, Yunming Su, Xianbiao Wang, Bingrui Li, Jing Chen, Diancai Sun, Fengxia Li, Shen Ma, Jiashu Li, Xianwei Bai, Ludong Li, Ranran Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title | Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title_full | Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title_fullStr | Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title_full_unstemmed | Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title_short | Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial |
title_sort | peony-glycyrrhiza decoction for antipsychotic-related hyperprolactinemia in patients with schizophrenia: a randomized controlled trial |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120814/ https://www.ncbi.nlm.nih.gov/pubmed/37089913 http://dx.doi.org/10.2147/NDT.S408314 |
work_keys_str_mv | AT wangzhongbao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT zhengyunshao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT fanyunli peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT fanyunming peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT suxianbiao peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT wangbingrui peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT lijing peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT chendiancai peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT sunfengxia peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT lishen peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT majiashu peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT lixianwei peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT bailudong peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial AT liranran peonyglycyrrhizadecoctionforantipsychoticrelatedhyperprolactinemiainpatientswithschizophreniaarandomizedcontrolledtrial |